Sorrento Therapeutics’ (NASDAQ: SRNE) share price is rallying premarket after the health regulatory authority for Mexico listed COVI-STIX on its official government website list of rapid antigen tests approved for emergency use in Mexico.
Sorrento’s COVI-STIX is a rapid diagnostic test for detecting the SARS-CoV-2 virus, with results taking approximately 15 minutes.
An independent study conducted by the Mexican government’s epidemiological department confirmed the validity of the test in 465 nasopharyngeal samples from symptomatic or uninfected people.
WELCOME BONUS - Free Share Bundle When You Invest £50!
Get up to £500 cashback for investing with IG.
Among all of the products on the current list, COVI-STIX outperformed for both sensitivity and specificity.
“We are very grateful to COFEPRIS for working with us closely on this review and listing us for use in Mexico,” stated Dr Henry Ji, Chairman and CEO of Sorrento.
“We look forward to working even more closely with the Mexican government to help deploy our test at scale. We have been building our manufacturing capacity in anticipation of this day and are ready to deliver tests in the tens of millions of units monthly.”
Sorrento Therapeutics’ share price is trading at $8.18 premarket, up 7.07%.
Should You Invest in Sorrento Therapeutics Shares?
One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It’s a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now